NCT04355156 2026-04-16
AXMUS-C
Imperial College London
Phase 2 Completed
Clinical Trials
41 trialsNCT01409200 2026-03-03
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04258956 2025-09-11
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Completed
NCT03826589 2025-06-11
ALARICE
The University of Hong Kong
Phase NA Completed
NCT04337970 2025-05-28
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02535533 2025-05-20
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1 Completed
NCT02597322 2025-04-06
AXIPAN
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT04562441 2025-01-10
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
Phase 2 Completed
NCT05904730 2024-12-30
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
Phase 1 Completed
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT03990571 2024-10-18
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01385059 2023-03-07
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02489695 2022-09-06
AXIPAP
Centre Leon Berard
Phase 2 Completed
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT02261207 2021-09-28
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT02762513 2021-05-05
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01140737 2021-03-18
Axi-STS
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Completed
NCT01321437 2021-01-20
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
University of California, Irvine
Phase 2 Completed
NCT01798446 2020-12-08
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Seoul National University Hospital
Phase 2 Completed
NCT01334112 2019-12-12
AXITINIB
University Health Network, Toronto
Phase 2 Completed
NCT00859118 2019-11-19
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
University of Wisconsin, Madison
Phase 1 Completed
NCT01540526 2019-11-19
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
University of Wisconsin, Madison
Phase 1 Completed
NCT02700568 2019-10-22
FavorAx
Kidney Cancer Research Bureau
Phase 2 Completed
NCT01490866 2019-09-24
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02857712 2019-08-30
SGC-AX14
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01562197 2019-01-24
AxiGII
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT03291314 2019-01-23
GliAvAx
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01435122 2018-10-02
A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01352728 2018-06-20
Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
Chinese University of Hong Kong
Phase 2 Completed
NCT01174238 2018-06-08
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT01558661 2017-11-28
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01211275 2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT01273662 2017-02-09
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT01469546 2016-08-29
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01486251 2016-02-10
AXUS
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Completed
NCT01334073 2015-07-23
EVAX
University Hospital, Bordeaux
Phase 1 Completed
NCT01529138 2015-04-13
Study of Axitinib and Temsirolimus in Solid Tumors
Emory University
Phase 1 Completed